Evidence map›Paper›PMID 26244713›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2015

Micro/nanofabricated platforms for oral drug delivery.

Cade B Fox, Jean Kim, Long V Le, Cameron L Nemeth, Hariharasudhan D Chirra, Tejal A Desai

Abstract readReview
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 110 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Vitamin DMolecules (Basel, Switzerland) · 2024
    Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Foundations of gastrointestinal-based drug delivery and future developments.Nature reviews. Gastroenterology & hepatology · 2022
    Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Cade B FoxDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158, USA.
Jean KimUC Berkeley & UCSF Graduate Program in Bioengineering, UCSF Mission Bay Campus, San Francisco, CA 94158, USA.
Long V LeUC Berkeley & UCSF Graduate Program in Bioengineering, UCSF Mission Bay Campus, San Francisco, CA 94158, USA.
Cameron L NemethUC Berkeley & UCSF Graduate Program in Bioengineering, UCSF Mission Bay Campus, San Francisco, CA 94158, USA.
Hariharasudhan D ChirraDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158, USA.
Tejal A DesaiDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158, USA; UC Berkeley & UCSF Graduate Program in Bioengineering, UCSF Mission Bay Campus, San Francisco, CA 94158, USA. Electronic address: Tejal.Desai@ucsf.edu.
University of California, San Francisco · USUniversity of California, Berkeley · USGraduate Theological Union · US

Funding

UCSF/UCB Joint Graduate Group in BIoengineeringT32GM008155 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DESAI, TEJAL A. · 1985 to 2020
$12.2M
PHARMACEUTICAL SCIENCES AND PHARMACOGENOMICST32GM007175 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AHITUV, NADAV, KROETZ, DEANNA L · 1985 to 2021
$7.1M
Mechanisms of nanostructure-enhanced transepithelial drug deliveryR01EB018842 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DESAI, TEJAL A. · 2014 to 2017
$1.4M
NIBIB NIH HHS R01 EB018842NIGMS NIH HHS 5T32GM007175-37NIGMS NIH HHS T32 GM007175NIGMS NIH HHS T32 GM008155NIGMS NIH HHS T32GM008155-29
6 · The paper itself

Abstract

The oral route of drug administration is most preferred due to its ease of use, low cost, and high patient compliance. However, the oral uptake of many small molecule drugs and biotherapeutics is limited by various physiological barriers, and, as a result, drugs suffer from issues with low solubility, low permeability, and degradation following oral administration. The flexibility of micro- and nanofabrication techniques has been used to create drug delivery platforms designed to address these barriers to oral drug uptake. Specifically, micro/nanofabricated devices have been designed with planar, asymmetric geometries to promote device adhesion and unidirectional drug release toward epithelial tissue, thereby prolonging drug exposure and increasing drug permeation. Furthermore, surface functionalization, nanotopography, responsive drug release, motion-based responses, and permeation enhancers have been incorporated into such platforms to further enhance drug uptake. This review will outline the application of micro/nanotechnology to specifically address the physiological barriers to oral drug delivery and highlight technologies that may be incorporated into these oral drug delivery systems to further enhance drug uptake.

Indexed as

Drug Delivery SystemsAdministration, OralAnimalsDelayed-Action PreparationsHumansIntestinal MucosaMicrotechnologyNanotechnologyPharmacokineticsDelayed-Action PreparationsMicrodeviceMicrofabricationNanofabricationNanotopographyOral drug deliveryTargeted delivery

Identifiers

PMID26244713
PMCPMC4656086
OpenAlexW1103169728

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.